Catalent re-ups manufacturing deal for Pfizer Liqui-Gels
Catalent Pharma Solutions has signed an exclusive long-term supply agreement with Pfizer.
As part of the agreement, Catalent has formulated and is manufacturing Pfizer’s new Advil Liqui-Gels Minis using its softgel platform OptiGel™ Mini technology.
The technology helps improve absorption and enables higher API concentrations into smaller capsules.
The agreement follows a 20-year collaboration on the development and manufacture of Advil® Liqui-Gels® (ibuprofen).
Catalent is manufacturing the product at its St. Petersburg, Florida, facility.
